Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Transgene Biotek has informed the Bombay Stock Exchange that the Statement of Deviation & Variation under SEBI's Regulation 32(1) is not applicable to the company for the quarter ended 30 September 2025. This is because the company did not raise any money through a public issue, rights issue, preferential issue, or Qualified Institutions Placement (QIP) during the quarter. The filing is a routine compliance confirmation, not a new fundraising event.
No impact on shareholders or the stock price. This is a standard regulatory clarification confirming that no fresh capital was raised, so there is nothing to report on the use of issue proceeds.